Details for Patent: 12,290,566

Which drugs does patent 12,290,566 protect, and when does it expire?

Patent 12,290,566 protects EMPAVELI and is included in one NDA.

This patent has ten patent family members in six countries.

Summary for Patent: 12,290,566

Title:	Dosing regimens and related compositions and methods
Abstract:	In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
Inventor(s):	Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
Assignee:	Jpharma Solutions GmbH , Apellis Pharmaceuticals Inc
Application Number:	US18/115,744
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 12,290,566

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes	12,290,566		Y			TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes	12,290,566		Y			TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY TWICE-WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014-001	May 14, 2021		RX	Yes	Yes	12,290,566		Y			TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 35 KG TO LESS THAN 50 KG WITH C3G OR PRIMARY IC-MPGN BY TWICE WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 810 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1

International Family Members for US Patent 12,290,566

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018386304
Australia	2024201445
European Patent Office	3724211